Inhibition of p38 MAPK in the brain through nasal administration of p38 inhibitor loaded in chitosan nanocapsules.
Nanomedicine (Lond)
; 14(18): 2409-2422, 2019 09.
Article
em En
| MEDLINE
| ID: mdl-31456488
ABSTRACT
Aim:
To determine whether a p38 MAPK inhibitor incorporated into nanoemulsion-based chitosan nanocapsules can reduce the activity of this kinase in the brain through their nasal administration in mice. Materials &methods:
We selected the p38 MAPK inhibitor PH797804, an ATP-competitive inhibitor of p38α encapsulated in nanoemulsion-based chitosan nanocapsules. Biological effect was evaluated in microglial and neuronal cells in vitro and in ex vivo and in vivo systems, in a mouse model of Alzheimer's disease.Results:
Encapsulated inhibitor retains enzymatic inhibitory activity and tissue penetration capacity in vitro, ex vivo and in vivo.Conclusion:
Nasal administration of chitosan nanocapsules can be an effective approach for brain-restricted reduction of p38 MAPK activity, thus reducing the side effects of systemic administration.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piridonas
/
Benzamidas
/
Encéfalo
/
Quitosana
/
Proteínas Quinases p38 Ativadas por Mitógeno
/
Inibidores de Proteínas Quinases
/
Nanocápsulas
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article